Apple smartwatch’s ECG sensor struggles to find its footing to tackle cardiovascular conditions

October 31, 2022 | Case Study

Apple smartwatches came to the forefront when they were one of the first to announce a dry electrode ECG sensor embedded within the Apple Watch 4 back in 2018. Before then, ECG detection was mostly something you could do only within a hospital. The announcement was met with a lot of excitement and enthusiasm, not just for health and wellness enthusiasts, but also for consumers suffering from cardiovascular conditions, particularly atrial fibrillation (AFib), which is a condition related to an irregular heartbeat in the upper chambers of the heart. The condition affects about 2%–4% of the world's adult population. However, four years and four iterations later (we are on Apple Watch 8 at the time of writing), Apple has yet to demonstrate value for Afib patients, and it is not for lack of trying.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978